Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Aurinia bounces on latest lupus nephritis readout

Aurinia Pharmaceuticals Inc. (TSX:AUP; NASDAQ:AUPH) shares jumped after the company said both doses of voclosporin (LX211) met the 48-week secondary efficacy endpoints in the Phase IIb AURA-LV trial to treat active lupus nephritis, with no new deaths or unexpected

Read the full 395 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE